Next Article in Journal
Tissue Elasticity as a Diagnostic Marker of Molecular Mutations in Morphologically Heterogeneous Colorectal Cancer
Previous Article in Journal
Blap-6, a Novel Antifungal Peptide from the Chinese Medicinal Beetle Blaps rhynchopetera against Cryptococcus neoformans
Previous Article in Special Issue
Blue Native PAGE–Antibody Shift in Conjunction with Mass Spectrometry to Reveal Protein Subcomplexes: Detection of a Cerebellar α1/α6-Subunits Containing γ-Aminobutyric Acid Type A Receptor Subtype
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 10
10.3390/ijms25105334
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Int. J. Mol. Sci. 2022, 23(20), 12687.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687

by
Anne V. Yagolovich
1,2,3,*,†,
Alina A. Isakova
1,2,†,
Artem A. Artykov
1,3,
Yekaterina V. Vorontsova
1,
Diana V. Mazur
1,
Nadezhda V. Antipova
1,
Marat S. Pavlyukov
1,
Mikhail I. Shakhparonov
1,
Anastasia M. Gileva
1,
Elena A. Markvicheva
1,
Ekaterina A. Plotnikova
4,
Andrey A. Pankratov
4,
Mikhail P. Kirpichnikov
1,2,
Marine E. Gasparian
1,‡ and
Dmitry A. Dolgikh
1,2,‡
1
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 117997 Moscow, Russia
2
Faculty of Biology, Lomonosov Moscow State University, 119192 Moscow, Russia
3
Manebio LLC, 115280 Moscow, Russia
4
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, P.A. Hertsen Moscow Oncology Research Institute, 125284 Moscow, Russia
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
‡
These authors contributed equally to this work.
Int. J. Mol. Sci. 2024, 25(10), 5334; https://doi.org/10.3390/ijms25105334
Submission received: 22 April 2024 / Accepted: 24 April 2024 / Published: 14 May 2024
(This article belongs to the Special Issue Advances in Protein-Protein Interactions)
Browse Figure
Versions Notes
In the original publication [1], there was a mistake in Figure 4D as published. Due to the similar lack of cytotoxic effects, the control 0.000 nM/DR5-B image was accidentally replaced with a part of the 0.005 nM/DR5-B image. However, the error does not have a critical impact on the results, since the lack of cytotoxicity of 0.005 nM DR5-B is also confirmed by the viability data (see Figure 4B). The authors sincerely apologize for the confusion. The corrected Figure 4 appears below.
To specifically clarify the conflicts of interest in the original publication [1], the corrected Conflicts of Interest appears here. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Conflicts of Interest

Dr. Anne V. Yagolovich and Mr. Artem A. Artykov were employed by the Manebio LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Reference

  1. Yagolovich, A.V.; Isakova, A.A.; Artykov, A.A.; Vorontsova, Y.V.; Mazur, D.V.; Antipova, N.V.; Pavlyukov, M.S.; Shakhparonov, M.I.; Gileva, A.M.; Markvicheva, E.A.; et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687. [Google Scholar] [CrossRef] [PubMed]
Ijms 25 05334 g001
Figure 4. Cytotoxicity of DR5-B and DR5-B–iRGD in primary human glioblastoma patient-derived neurospheres. (A) Surface expression of the DR5 and integrin αvβ3 receptors determined by flow cytometry. (B) Primary human glioblastoma cell lines 11 and 267 were incubated with DR5-B or DR5-B–iRGD for 72 h, and viability was analyzed by the Alamar Blue assay. The data were displayed as mean ± SD from at least three replicates. * p < 0.005 and ** p < 0.0005 indicate significant difference from the control according to one-way ANOVA followed by Dunnett’s post hoc test. (C) IC50 values of DR5-B and DR5-B–iRGD were determined as the drug concentrations resulting in the 50% inhibition of cell growth by nonlinear regression in GraphPad Prism 8 software. # p < 0.005 indicates significant difference from the control according to Student’s t-test. (D) Morphology of primary patient-derived neurospheres (Line 267) treated with DR5-B or DR5-B-iRGD. Scale bar is 200 µm.
Figure 4. Cytotoxicity of DR5-B and DR5-B–iRGD in primary human glioblastoma patient-derived neurospheres. (A) Surface expression of the DR5 and integrin αvβ3 receptors determined by flow cytometry. (B) Primary human glioblastoma cell lines 11 and 267 were incubated with DR5-B or DR5-B–iRGD for 72 h, and viability was analyzed by the Alamar Blue assay. The data were displayed as mean ± SD from at least three replicates. * p < 0.005 and ** p < 0.0005 indicate significant difference from the control according to one-way ANOVA followed by Dunnett’s post hoc test. (C) IC50 values of DR5-B and DR5-B–iRGD were determined as the drug concentrations resulting in the 50% inhibition of cell growth by nonlinear regression in GraphPad Prism 8 software. # p < 0.005 indicates significant difference from the control according to Student’s t-test. (D) Morphology of primary patient-derived neurospheres (Line 267) treated with DR5-B or DR5-B-iRGD. Scale bar is 200 µm.
Ijms 25 05334 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Yagolovich, A.V.; Isakova, A.A.; Artykov, A.A.; Vorontsova, Y.V.; Mazur, D.V.; Antipova, N.V.; Pavlyukov, M.S.; Shakhparonov, M.I.; Gileva, A.M.; Markvicheva, E.A.; et al. Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687. Int. J. Mol. Sci. 2024, 25, 5334. https://doi.org/10.3390/ijms25105334

AMA Style

Yagolovich AV, Isakova AA, Artykov AA, Vorontsova YV, Mazur DV, Antipova NV, Pavlyukov MS, Shakhparonov MI, Gileva AM, Markvicheva EA, et al. Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687. International Journal of Molecular Sciences. 2024; 25(10):5334. https://doi.org/10.3390/ijms25105334

Chicago/Turabian Style

Yagolovich, Anne V., Alina A. Isakova, Artem A. Artykov, Yekaterina V. Vorontsova, Diana V. Mazur, Nadezhda V. Antipova, Marat S. Pavlyukov, Mikhail I. Shakhparonov, Anastasia M. Gileva, Elena A. Markvicheva, and et al. 2024. "Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687" International Journal of Molecular Sciences 25, no. 10: 5334. https://doi.org/10.3390/ijms25105334

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop